International Review of Ophthalmology

Previous Articles     Next Articles

Research progress of mesenchymal stem cells for the treatment of retinitis pigmentosa

DONG Li, WEI Wen-bin   

  1. Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Key Laboratory of Ophthalmology ＆ Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
  • Received:2017-08-21 Online:2017-12-22 Published:2017-12-21
  • Contact: WEI Wen-bin, Email: weiwenbintr@163.com
  • Supported by:

    Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20150201); Science & Technology Project of Beijing Municipal Science & Technology Commission (Z151100001615052); National Natural Science Foundation of China (81570891)

Abstract:

Retinitis pigmentosa (RP) is a main cause of blindness throughout the world. So far, there is no effective way to prevent or reverse the development of RP. Mesenchymal stem cell (MSC) is a kind of stem cells, which can differentiate into a specific type of retinal cells when induced in vivo or in vitro. MSCs can repair and protect the retinal function by cell replacement, neuroprotection and vascular regulation, which provide a cellular replacement therapy for RP.(Int Rev Ophthalmol,  2017,  41:   395-399)